Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 of ELX-02 for Cystic Fibrosis

Trial Profile

A Phase 2 of ELX-02 for Cystic Fibrosis

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs ELX 02 (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Sponsors Eloxx Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2018 According to an Eloxx Pharmaceuticals media release, the company expects to enroll more than 24 patients and report top-line data from this study in 2019.
    • 07 Aug 2018 According to an Eloxx Pharmaceuticals media release, CTA has been approved by the Federal Agency for Medicines and Health Products (the FAMHP) in Belgium. The European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN) has reviewed and approved the protocol in cystic fibrosis patients with a G542X mutation and has given it 'high priority' status. The trial is expected to initiate in the fourth quarter of 2018.
    • 08 Jun 2018 According to an Eloxx Pharmaceuticals media release, the company is planning to initiate this trial later in 2018,pending regulatory clearance, and are pleased the European Cystic Fibrosis Society-Clinical Trial Network has reviewed and approved our protocol with a high priority rating.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top